
Memel Biotech Announces Collaboration with THERABEST on Developing Exosome-Based and other Innovative Cell Therapies
Klaipeda Lithuania and Seoul, Korea, April 23,2024 – Memel Biotech (Memel) today announced it has signed an MoU with THERABEST Korea (THERABEST) to research and develop exosome and other innovative cell therapies. Memel provides integrated advanced therapy development and manufacturing services from its state-of-art facility strategically located for EU markets at the Baltic seaport of Klaipeda, Lithuania. THERABEST is a discovery/clinical stage biotech company leveraging its next-generation EiNKTM platform to develop enhanced iPSC-derived immune cell therapies.
The two companies are natural collaboration partners having both gathered a wealth of cell therapy experience in product formulation, process and analytical development, process scale-up and automation, GMP manufacturing, validation and logistics. This is complemented by up-to-date knowhow of regulatory approval demands and processes in all key markets.
Memel CEO Agnė Vaitkevičienė commented: “We are delighted to sign this MoU with THERABEST who are one of the leading innovators in the field with their enhanced NK cell therapies. Together we will now define research projects that utilise our complementary strengths in exciting areas such as exosomes. This could also involve applying jointly for research funding.”
THERABEST CEO Pyung-Suk Ki commented: “Through the signing of this MoU, it is anticipated that by actively harnessing the integrated infrastructure of Memel biotech’s new drug development platform, THERABEST will expedite the swift progression of a diverse array of next-generation innovative products currently in development, leading them to the global clinical stage.”
The MoU is also a prime example of the growing life sciences collaboration between Lithuania and Korea and was signed in Seoul on March 25 during a highly successful Lithuanian Life Sciences delegation visit. The Ambassador of Lithuania to South Korea Ričardas Šlepavičius said: “The signing of the MOU between Memel Biotech and THERABEST signifies a major milestone in the deepening of biotech ties between Lithuania and South Korea. This partnership highlights our dedication to strengthening collaboration between countries in the biotech industry, leveraging collective innovation and expertise to tackle global challenges and lead pioneering advancements in healthcare and beyond. I truly believe that this partnership will set a benchmark for future projects between Lithuania and South Korea, demonstrating the blueprint for fruitful future collaboration.”
About Memel Biotech
Memel Biotech is a pioneering Lithuanian company that specializes in providing comprehensive Contract Development and Manufacturing Organization (CDMO) services tailored to the specific needs of Advanced Therapy Medicinal Products (ATMPs) development. We offer GMP-compliant infrastructure, encompassing cutting-edge facilities and a globally diverse team of experts. With a focus on precision medicine research, drug development, and commercialization, we are your trusted partner for advancing ATMPs from concept to clinical reality.
About Therabest
Therabest is a discovery/clinical-stage biotech company focusing on developing immunotherapy for allogeneic adoptive transfer and biologics that improve well-being. Programs include Off-the-Shelf production of immune cells for universal cell therapy products as well as precision biologics to educate the immune system to target/attack specific abnormal cells as well as to enhance the immune response to eliminate hematological and solid cancer. Visit www.therabest.co.kr/en/.